Novo Nordisk shares rise as Biden proposes obesity care coverage
Changes key words for media clients. No change to text
COPENHAGEN, Nov 26 (Reuters) -Shares of Danish weight-loss drug maker Novo Nordisk NOVOb.CO rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid.
"This is an important step forward for patients," Novo Nordisk said in a statement commenting on the proposal, adding that the coverage could become effective in 2026.
The stock pared initial gains of as much as 4.9% to trade 1.3% higher at 1236 GMT.
Current rules for the Medicare and Medicaid government health insurance programmes cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.
The White House said in a statement the proposal could lower out-of-pocket costs for weight-loss drugs by up to 95%, expanding access to millions of Americans.
Nordnet analyst Per Hansen said Novo's share move came on the back of the proposal, with U.S. peer Eli Lilly LLY.N also rising in premarket trade.
Separately, a would-be challenger in the fast-growing obesity therapy market, Amgen AMGN.O, said its experimental drug MariTide led to an average weight loss of up to 20% in a mid-stage trial with overweight or obese participants.
Amgen's shares were down nearly 8% ahead of the U.S. market open, however, as the data fell short of investor expectations.
Reporting by Stine Jacobsen in Copenhagen, Jesus Calero in Gdansk, Ludwig Burger in Frankfurt; editing by Terje Solsvik and Jason Neely
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
